Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vir Biotechnology Launches Final ECLIPSE Trial, Advancing Full Registrational Program For Chronic Hepatitis Delta

Author: Benzinga Newsdesk | August 06, 2025 08:17am
  • ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3
  • ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company's registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated. ECLIPSE 3 is a Phase 2b trial designed to compare the combination of tobevibart and elebsiran to bulevirtide treatment in patients with CHD. ECLIPSE 3 will provide important supportive data to help establish access and reimbursement in key markets.

Posted In: VIR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist